Adam Ruth
Overview
Explore the profile of Adam Ruth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bessler J, Fazzone W, Sladicka N, Ruth A
Curr Med Res Opin
. 2023 Jul;
39(9):1271-1277.
PMID: 37497556
Objective: Understanding the healthcare provider (HCP) journey of discovering and consuming medical and scientific information is critical for optimizing publication reach. A survey was conducted in 2019-2020 to understand how...
2.
Earley W, Durgam S, Lu K, Ruth A, Nemeth G, Laszlovszky I, et al.
J Affect Disord
. 2017 Oct;
226:239-244.
PMID: 29017067
Background: Rates of response and remission are measures that endorse the clinical significance of treatment. Cariprazine is FDA approved for the acute treatment of schizophrenia and manic or mixed episodes...
3.
Khan A, Durgam S, Tang X, Ruth A, Mathews M, Gommoll C
Prim Care Companion CNS Disord
. 2016 Aug;
18(2).
PMID: 27486544
Objective: To investigate vilazodone, currently approved for major depressive disorder in adults, for generalized anxiety disorder (GAD). Method: Three randomized, double-blind, placebo-controlled studies showing positive results for vilazodone (2,040 mg/d)...
4.
Clayton A, Durgam S, Tang X, Chen C, Ruth A, Gommoll C
Neuropsychiatr Dis Treat
. 2016 Jul;
12:1467-76.
PMID: 27382289
Background: Vilazodone has been shown to reduce core symptoms of generalized anxiety disorder (GAD) in three randomized, double-blind, placebo-controlled trials. Since sexual dysfunction (SD) is not well characterized in GAD,...
5.
McIntyre R, Gommoll C, Chen C, Ruth A
CNS Spectr
. 2016 Jun;
21(5):385-392.
PMID: 27292817
Objective: A post hoc analysis evaluated the effects of levomilnacipran ER on individual symptoms and symptom domains in adults with major depressive disorder (MDD). Methods: Data were pooled from 5...
6.
Durgam S, Cutler A, Lu K, Migliore R, Ruth A, Laszlovszky I, et al.
J Clin Psychiatry
. 2015 Dec;
76(12):e1574-82.
PMID: 26717533
Objective: This phase 3 study evaluated the efficacy, safety, and tolerability of cariprazine in patients with acute exacerbation of schizophrenia. Method: This multinational, randomized, double-blind, placebo- and active-controlled study was...
7.
Cutler A, Gommoll C, Chen C, Greenberg W, Ruth A
Prim Care Companion CNS Disord
. 2015 Dec;
17(3).
PMID: 26644957
Objective: In this post hoc analysis, improvement in functional impairment in patients with major depressive disorder (MDD) treated with levomilnacipran extended release (ER) was evaluated by assessing shifts from more...
8.
Freeman M, Fava M, Gommoll C, Chen C, Greenberg W, Ruth A
Int Clin Psychopharmacol
. 2015 Nov;
31(2):100-9.
PMID: 26584326
The aim of this study was to evaluate the effects of levomilnacipran extended-release (ER) on depression-related fatigue in adults with major depressive disorder. Post-hoc analyses of five phase III trials...
9.
Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S
Eur Neuropsychopharmacol
. 2015 Oct;
25(11):1882-91.
PMID: 26419293
Bipolar I disorder is a chronic disorder characterized by episodic recurrences of mania, depression, and mixed affective states interspersed with periods of full or partial remission; subsyndromal residual symptoms between...
10.
Kane J, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, et al.
J Clin Psychopharmacol
. 2015 Jun;
35(4):367-73.
PMID: 26075487
This phase III study evaluated the efficacy and safety of cariprazine, a dopamine D3 and D2 receptor partial agonist with preferential binding to D3 receptors, in patients with acute exacerbation...